Cargando…
Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
Background and Objectives: Postoperative adjuvant therapy with uracil and tegafur (UFT) is often used for stage II colon cancer in Japan, but a limited number of studies have investigated the effects of UFT in these patients. Materials and Methods: We conducted a population-based cohort study in pat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864689/ https://www.ncbi.nlm.nih.gov/pubmed/36676634 http://dx.doi.org/10.3390/medicina59010010 |
_version_ | 1784875645777477632 |
---|---|
author | Chen, Po-Huang Jhou, Hong-Jie Chung, Chi-Hsiang Wu, Yi-Ying Huang, Tzu-Chuan Lee, Cho-Hao Chien, Wu-Chien Chen, Jia-Hong |
author_facet | Chen, Po-Huang Jhou, Hong-Jie Chung, Chi-Hsiang Wu, Yi-Ying Huang, Tzu-Chuan Lee, Cho-Hao Chien, Wu-Chien Chen, Jia-Hong |
author_sort | Chen, Po-Huang |
collection | PubMed |
description | Background and Objectives: Postoperative adjuvant therapy with uracil and tegafur (UFT) is often used for stage II colon cancer in Japan, but a limited number of studies have investigated the effects of UFT in these patients. Materials and Methods: We conducted a population-based cohort study in patients with resected stage II colon cancer comparing the outcomes after postoperative adjuvant chemotherapy with UFT with an observation-only group. The data were collected from the Taiwan National Health Insurance Research Database from 2000 to 2015. The outcomes of the study were disease-free survival (DFS) and overall survival (OS). The hazard ratios (HRs) were calculated using multivariate Cox proportional hazard regression models. Results: No differences in the DFS and OS were detected between the UFT (1137 patients) and observation (2779 patients) cohorts (DFS: adjusted HR 0.702; 95% confidence interval (CI) 0.489–1.024; p = 0.074) (OS: adjusted HR 0.894; 95% CI 0.542–1.186; p = 0.477). In the subgroup analyses of the different substages, UFT prolonged DFS in patients with stage IIA colon cancer (adjusted HR 0.652; 95% CI 0.352–0.951; p = 0.001) compared with DFS in the observation cohort, but no differences in the OS were detected (adjusted HR 0.734; 95% CI 0.475–1.093; p = 0.503). Conclusions: Our results show that DFS improved significantly in patients with stage IIA colon cancer receiving UFT as a postoperative adjuvant chemotherapy compared with DFS in the observation group. |
format | Online Article Text |
id | pubmed-9864689 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98646892023-01-22 Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer Chen, Po-Huang Jhou, Hong-Jie Chung, Chi-Hsiang Wu, Yi-Ying Huang, Tzu-Chuan Lee, Cho-Hao Chien, Wu-Chien Chen, Jia-Hong Medicina (Kaunas) Article Background and Objectives: Postoperative adjuvant therapy with uracil and tegafur (UFT) is often used for stage II colon cancer in Japan, but a limited number of studies have investigated the effects of UFT in these patients. Materials and Methods: We conducted a population-based cohort study in patients with resected stage II colon cancer comparing the outcomes after postoperative adjuvant chemotherapy with UFT with an observation-only group. The data were collected from the Taiwan National Health Insurance Research Database from 2000 to 2015. The outcomes of the study were disease-free survival (DFS) and overall survival (OS). The hazard ratios (HRs) were calculated using multivariate Cox proportional hazard regression models. Results: No differences in the DFS and OS were detected between the UFT (1137 patients) and observation (2779 patients) cohorts (DFS: adjusted HR 0.702; 95% confidence interval (CI) 0.489–1.024; p = 0.074) (OS: adjusted HR 0.894; 95% CI 0.542–1.186; p = 0.477). In the subgroup analyses of the different substages, UFT prolonged DFS in patients with stage IIA colon cancer (adjusted HR 0.652; 95% CI 0.352–0.951; p = 0.001) compared with DFS in the observation cohort, but no differences in the OS were detected (adjusted HR 0.734; 95% CI 0.475–1.093; p = 0.503). Conclusions: Our results show that DFS improved significantly in patients with stage IIA colon cancer receiving UFT as a postoperative adjuvant chemotherapy compared with DFS in the observation group. MDPI 2022-12-20 /pmc/articles/PMC9864689/ /pubmed/36676634 http://dx.doi.org/10.3390/medicina59010010 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Po-Huang Jhou, Hong-Jie Chung, Chi-Hsiang Wu, Yi-Ying Huang, Tzu-Chuan Lee, Cho-Hao Chien, Wu-Chien Chen, Jia-Hong Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer |
title | Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer |
title_full | Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer |
title_fullStr | Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer |
title_full_unstemmed | Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer |
title_short | Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer |
title_sort | benefit of uracil–tegafur used as a postoperative adjuvant chemotherapy for stage iia colon cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864689/ https://www.ncbi.nlm.nih.gov/pubmed/36676634 http://dx.doi.org/10.3390/medicina59010010 |
work_keys_str_mv | AT chenpohuang benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer AT jhouhongjie benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer AT chungchihsiang benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer AT wuyiying benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer AT huangtzuchuan benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer AT leechohao benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer AT chienwuchien benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer AT chenjiahong benefitofuraciltegafurusedasapostoperativeadjuvantchemotherapyforstageiiacoloncancer |